SEATTLE, October 4, 2022 /PRNewswire/ — Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for high-prevalence diseases, today announced the release of data demonstrating a needle-free recombinant vaccine, produced from spirulina, that protects against malaria. The research, carried out in collaboration with the University of Washingtonwas published in the peer-reviewed journal, Nature Partner Journals (NPJ) Vaccines.
Lumen Bioscience has pioneered genetic engineering methods to strongly express the bioactive proteins of spirulina. The published research details how this platform was used to express a malaria protein antigen that can be administered intranasally and then boosted with a simple oral boost. Treated mice demonstrate protection against subsequent malaria challenge. The low cost and scalability of Lumen’s production platform, combined with easy, needle-free administration, could significantly expand real-world access to malaria vaccines.
“We are excited to work with Lumen on this potentially game-changing application of their unique technology platform,” said lead author Sean Murphy, MD, Ph.D., associate professor at University of Washington and clinical researcher at the Seattle Malaria Clinical Trials Center. “Significant progress has been made in the area of recombinant malaria vaccines, but real-world access remains difficult due to infrastructure and supply chain limitations and cost sensitivity in the most areas where malaria is endemic. This new approach may help overcome these concerns.
A free online version of the post – “Needle Free Spirulina Product Plasmodium falciparum circumsporozoite vaccination provides sterile protection against pre-erythrocytic malaria in mice” – is available at NPJ vaccines here. (DOI: 10.1038/s41541-022-00534-5).
“Using edible spirulina as a malaria vaccine platform offers a novel approach to vaccine development at scales, cost and delivery that could greatly improve access compared to traditional vaccination approaches,” said jim robertMD, Ph.D., co-founder and chief scientific officer of Lumen Bioscience.
Lumen Bioscience discovers, develops and manufactures biological drug candidates for widespread diseases, many of which currently lack effective treatments. The company’s unique drug development and manufacturing platform offers the potential to transform the biologics industry through increased speed, mass market scale and exponentially lower costs than current approaches. Lumen’s clinical pipeline includes investigational biologic drugs for It’s hard infection, inflammatory bowel disease, Covid-19, cardiometabolic disease, norovirus and traveller’s diarrhea. For more information, visit: www.lumen.bio. You can also follow Lumen on LinkedIn, TwitterInstagram and Facebook, and also subscribe to Lumen News alerts.
View original content to download multimedia: https://www.prnewswire.com/news-releases/lumen-bioscience-announces-publication-in-npj-vaccines-of-preclinical-data-demonstrating-needle-free-spirulina -produced-vaccination-providing-protection-against-malaria-301639757.html
SOURCE Light Bioscience